Connect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Update

Connect Biopharma Holdings Limited (NASDAQ:CNTB) was the target of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 10,300 shares, a decrease of 77.9% from the February 28th total of 46,700 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 20,500 shares, the days-to-cover ratio is presently 0.5 days.

Connect Biopharma Price Performance

Shares of CNTB traded up $0.03 during midday trading on Friday, reaching $0.79. 4,374 shares of the stock were exchanged, compared to its average volume of 50,103. The company’s 50 day moving average is $0.91 and its two-hundred day moving average is $1.08. Connect Biopharma has a 52 week low of $0.76 and a 52 week high of $2.66.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Callan Capital LLC lifted its position in shares of Connect Biopharma by 91.3% in the 4th quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock worth $110,000 after purchasing an additional 38,177 shares during the period. Choreo LLC purchased a new stake in Connect Biopharma during the fourth quarter worth $204,000. Finally, Catalina Capital Group LLC purchased a new stake in Connect Biopharma during the fourth quarter worth $66,000. Hedge funds and other institutional investors own 58.72% of the company’s stock.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.